Harvard Bioscience (HBIO) Other Non-Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Non-Current Liabilities data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 19.07% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 19.07% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 4.22% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.1 million, down from $1.3 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for HBIO reached as high as $1.6 million in Q2 2024 and fell as low as $418000.0 in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $1.2 million across 5 years, with a median of $1.3 million in 2025.
• Across the five-year window, Other Non-Current Liabilities slumped 83.53% in 2022 and surged 150.24% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $1.0 million in 2022, then jumped by 46.72% to $1.5 million in 2023, then dropped by 14.97% to $1.3 million in 2024, then rose by 4.22% to $1.3 million in 2025, then declined by 12.39% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.1 million in Q1 2026, $1.3 million in Q4 2025, and $1.5 million in Q3 2025.